common.study.topics.clinical

Exercise Capacity in Subjects with Heart Failure

common.study.values.description

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Omecamtiv Mecarbil

Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing

Drug - Placebo

Oral placebo twice daily for up to 20 weeks

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance

common.study.values.clinical-trial-id

NCT03759392

participant.views.study.view.id

dyPpVb